Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT00003778 Completed - Ovarian Cancer Clinical Trials

Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma

Start date: April 1999
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have recurrent or metastatic soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00003773 Completed - Ovarian Cancer Clinical Trials

IM-862 in Treating Patients With Recurrent Ovarian Cancer

Start date: February 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with chemotherapy and surgery.

NCT ID: NCT00003772 Completed - Ovarian Cancer Clinical Trials

Quality-of-Life Assessment in Patients With Ovarian Cancer

Start date: January 1999
Phase: N/A
Study type: Observational

RATIONALE: Quality-of-life assessment in patients undergoing cancer treatment may help determine the intermediate- and long-term effects of treatment. PURPOSE: This clinical trial studies the quality of life in patients with ovarian cancer.

NCT ID: NCT00003763 Completed - Ovarian Cancer Clinical Trials

Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer

Start date: December 8, 1997
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer. PURPOSE: Diagnostic trial to study the effectiveness of radiolabeled folic acid plus imaging in detecting ovarian cancer.

NCT ID: NCT00003733 Active, not recruiting - Ovarian Cancer Clinical Trials

Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer

Start date: December 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of sequential chemotherapy in treating patients with residual disease following surgery for stage IIB, stage III, or stage IV ovarian cancer.

NCT ID: NCT00003732 Completed - Ovarian Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer

Start date: September 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of topotecan combined with carboplatin and paclitaxel in treating patients who have stage II, stage III, or stage IV ovarian cancer.

NCT ID: NCT00003718 Active, not recruiting - Ovarian Cancer Clinical Trials

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Start date: September 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced soft tissue sarcoma.

NCT ID: NCT00003695 Completed - Ovarian Cancer Clinical Trials

Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer

Start date: May 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with surgery may kill more tumor cells. It is not yet known whether chemotherapy plus surgery is more effective than chemotherapy alone in treating patients with stage II or stage III ovarian cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with or without surgery in treating patients with stage II or stage III ovarian cancer.

NCT ID: NCT00003670 Completed - Ovarian Cancer Clinical Trials

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Start date: October 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with metastatic refractory ovarian cancer or primary peritoneal cancer.

NCT ID: NCT00003657 Completed - Lung Cancer Clinical Trials

High-dose ICE With Amifostine

Start date: July 1998
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.